| Description |
Children with spinal muscular atrophy (SMA) exhibit diminished lean body mass and increased fat mass compared to healthy peers; conditions that limit mobility, aggravate orthopedic issues, and can potentially affect glucose tolerance and insulin sensitivity. It is unclear whether changes in body composition increase the risk for developing metabolic disease such as type II diabetes in this population. The aim of this pilot study was to determine whether preadolescents with SMA type II display impaired glucose tolerance after glucose loading. Data for 6 preadolescents (ages 7-11 years) with SMA type II were collected during an oral glucose tolerance test (OGTT). Baseline lab values were taken after an overnight fast to assess hemoglobin A1c, insulin-like growth factor 1 (IGF-1), blood glucose, insulin, glucagon, alanine, cortisol, and urinary ketones. Anthropometric measures and dual-energy x-ray absorptiometry (DEXA) scans evaluated body composition. Data from the OGTT indicate that 3 of the 6 patients exhibited impaired glucose tolerance with blood glucose levels ˃140 mg/dL. Based on homeostasis model assessment for insulin resistance (HOMA-IR) values, 4 of the 6 patients demonstrated insulin resistance and all 6 patients displayed hyperinsulinemia. Furthermore, DEXA analyses on all patients revealed high body fat percentages, with mean values of 71. 6% ± 13. 1. The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type . The pilot data provide evidence of glucose and insulin abnormalities in SMA type II patients. Screening protocols, such as an OGTT, may be beneficial in assessing and tracking SMA patient risk for metabolic disease. This knowledge may influence dietary management of patients with SMA and provide further insight into glucose metabolism abnormalities in the population. |
